Alwin Capital Alwin Capital Alwin Capital

Alwin Capital

Identifying life science breakthroughs to address unmet clinical needs, we invest in translational medicine frontiers to capture China opportunities.

Positioning

Alwin Capital is a professional venture capital in China specializing in life science investments. Driven by theme-focused research in life science, Alwin Capital has developed investment strategies that capture outstanding opportunities for innovative diagnostic and therapeutic developments. We are committed to the long-term investment in life science with the pursuit of the excess investment return based on the scientific insights.

Founded in 2015, Alwin Capital was formed by the veterans in capital market, bringing in decades of experience in China healthcare investment. Alwin Capital is currently managing both RMB and dollar funds, around $500 million in AUM, having invested in dozens of companies in life science and cultivated a bunch of leading companies in respective segments.

Portfolio

Over the past two decades, life science discoveries have been progressively transformed into clinical applications, revealing a whole new horizon for healthcare industries. In the theme line based on gene sequencing, the industrial chain of molecular diagnosis has developed in an all-round way. In the theme line based on gene synthesis, drug research and development has entered the macromolecular platform from the small molecular platform, and then entered the living drug platform. In the theme line based on gene editing, new clinical technologies such as gene therapy and nucleic acid drugs have infiltrated into the real clinical scenario. At the same time, life science, driven by artificial intelligence technology, has stepped a new development stage of digital life and precision medicine.

Under the current background of the development of life science and clinical medicine, adhering to the professional investment research in life science and the profound understanding of portfolio management, Alwin Capital has formed a systematic investment layout covering Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services and AI Applications.

  • alwin capital - Edigene

    Edigene

    The leader in gene editing new drug R&D in China with its product for β-thalassemia obtaining the first IND of gene therapy drugs in China

  • Reforgene

    The company with cutting-edge CRISPR technology in both in-vitro and in-vivo gene therapy product pipelines

  • NuiGene

    Innovative gene therapy company based on both AAV platform and CRISPR technology

  • Abogen

    The leader in mRNA new drug R&D in China with its preventive mRNA vaccine for Covid-19 has already in global clinical phase III

  • Immorna

    mRNA drug R&D company with systematic layout in vaccines of infectious diseases and I/O drugs

  • Neocura

    mRNA drug R&D company with pipelines of tumor neoantigen vaccines and other I/O drugs

  • Cell Therapy-Uni-CAR

    CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia

  • Immupeudics Medecine

    CTLs cell therapy development company for solid tumors and explored mRAN technology platform

  • Xbiome

    Microbiome drug R&D company in China with global leading progress and advancement

  • Bliss Bio

    ADC drug R&D company with a seasoned management team

  • Kira Pharma

    Clinical stage complement drug R&D company founded by globally prestigious scientist

  • Comgen

    Clinical stage First-in-Class complement drug R&D company

  • Adlai Nortye

    O/I drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.

  • Maybiomatrix

    A leading company using engineered stem cells to develop regenerative aesthetic innovative products.

  • Cancer Liquid Biopsy-Genecast

    The leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis

  • Mass Spectrometry Testing-Yingsheng Biology

    The key player in mass spectrometry testing market with a pipeline covering core products in China

  • Genetic Disease Testing-Chigene

    Genetic disease testing company with the largest database of genetic disease patients in China

  • Molecular Pathology Platform-Geneis:

    Multi-platform molecular pathology service provider to hospitals with comprehensive capabilities

  • Forensic DNA Testing-SuperBio

    The leader in forensic DNA testing with patented technologies and devices in China

  • DTC Gene Testing-23 MoFang

    The largest DTC gene testing company in China accounting for 40% market share

  • Synbio Tech

    High-throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies

  • Frasergen

    Scientific research service provider with advanced 3rd generation gene sequencing techniques

  • ONT Nanopore Sequencing-Qitan Tech

    ONT nanopore sequencer R&D company with the most advanced progress in China

  • Micro Droplet Platform-Sniper

    Digital PCR R&D company with innovative droplet generation technology platform

  • Edge Medical

    The leading surgical robot company in China with both single-hole and multi-hole endoscopic surgical robots in the pipeline

  • Rossum Robot

    A star-up company in the field of orthopedic robotics with its pelvic fracture reduction surgical robot holding global advancement

  • R&D

    The R&D company of high-value consumables for neural intervention with a complete product pipeline

  • HeartHill

    A cardiac mechanical circulatory support system R&D company with leading progress in China

  • FFR-CT AI Software-Keya Medical

    The leading AI image diagnosis company whose FFR-CT approved as the first AI Class III medical device by CFDA

  • Radiotherapy AI Software-Datu Medical

    AI imaging software company of radiotherapy with its planning software was first approved as the Class III medical device by CFDA

  • Click

    Digital manufacturer of invisible appliance based on automatic 3D printing technology

  • alwin capital - Edigene

    Edigene

    The leader in gene editing new drug R&D in China with its product for β-thalassemia obtaining the first IND of gene therapy drugs in China

  • Reforgene

    The company with cutting-edge CRISPR technology in both in-vitro and in-vivo gene therapy product pipelines

  • NuiGene

    Innovative gene therapy company based on both AAV platform and CRISPR technology

  • Abogen

    The leader in mRNA new drug R&D in China with its preventive mRNA vaccine for Covid-19 has already in global clinical phase III

  • immorna

    mRNA drug discovery company with systematic layout in vaccines of infectious diseases and I/O drugs

  • Neocura

    mRNA R&D company with pipelines of tumor neoantigen vaccines and other I/O drugs

  • Cell Therapy-Uni-CAR

    CAR-T cell therapy company with its first-in-class candidate of IL-6 knockdown CD19 CAR-T targeting CNS leukemia

  • Immupeudics Medecine

    CTLs cell therapy development company for solid tumors and explored mRAN technology platform

  • Xbiome

    Microbiome drug R&D company in China with global leading progress and advancement

  • Bliss Bio

    ADC drug R&D company with a seasoned management team

  • Kira Pharma

    Clinical stage complement drug R&D company founded by globally prestigious scientist

  • Comgen

    Clinical stage First-in-Class complement drug R&D company

  • Adlai Nortye

    O/I drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.

  • Maybiomatrix

    A leading company using engineered stem cells to develop regenerative aesthetic innovative products.

  • Cancer Liquid Biopsy-Genecast

    The leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis

  • Mass Spectrometry Testing-Yingsheng Biology

    The key player in mass spectrometry testing market with a pipeline covering core products in China

  • Genetic Disease Testing-Chigene

    Genetic disease testing company with the largest database of genetic disease patients in China

  • Molecular Pathology Platform-Geneis:

    Multi-platform molecular pathology service provider to hospitals with comprehensive capabilities

  • Forensic DNA Testing-SuperBio

    The leader in forensic DNA testing with patented technologies and devices in China

  • DTC Gene Testing-23 MoFang

    The largest DTC gene testing company in China accounting for 40% market share

  • Synbio Tech

    High-throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies

  • Frasergen

    Scientific research service provider with advanced 3rd generation gene sequencing techniques

  • ONT Nanopore Sequencing-Qitan Tech

    ONT nanopore sequencer R&D company with the most advanced progress in China

  • Micro Droplet Platform-Sniper

    Digital PCR R&D company with innovative droplet generation technology platform

  • Edge Medical

    The leading surgical robot company in China with both single-hole and multi-hole endoscopic surgical robots in the pipeline

  • Rossum Robot

    A star-up company in the field of orthopedic robotics with its pelvic fracture reduction surgical robot holding global advancement

  • R&D

    The R&D company of high-value consumables for neural intervention with a complete product pipeline

  • HeartHill

    A cardiac mechanical circulatory support system R&D company with leading progress in China

  • FFR-CT AI Software-Keya Medical

    The leading AI image diagnosis company whose FFR-CT approved as the first AI Class III medical device by CFDA

  • Radiotherapy AI Software-Datu Medical

    AI imaging software company of radiotherapy with its planning software was first approved as the Class III medical device by CFDA

  • Click

    Digital manufacturer of invisible appliance based on automatic 3D printing technology

Team

Alwin’s founding partners have been working together for more than ten years, building a strong team culture and mutual trust over the course of their careers. They know science and believe in the power of investment research. They all work in the front line to explore and capture the investment opportunities in life science.

孙雅娜
Yana Sun Ph.D., CFA

Founding Partner
  • Medical Doctor from Peking Union Medical College
  • Managing Director with 13 years working experience at CICC
  • Was the top ranked healthcare equity analyst in China capital market
  • Was Head of Strategic Research and Head of Wealth Investment
  • Highly forward-looking judgment on industry and capital market

师惠京
Huijing Shi

M.S. from University of International Business and Economics
Founding Partner
  • M.S. from University of International Business and Economics
  • COO at CICC fund of hedge funds, managing over RMB 5 Billion across 10 funds
  • Strong capability in financial risk control and fund operation
  • Comprehensive network among top financial institutions in China

刘嘉运
Jiayun Liu

M.S. from Hong Kong University
Partner
  • MPH from Hong Kong University, B.S Med from Fudan University
  • Years of work experience in the field of medicine across primary and secondary markets
  • Accumulated rich research experience in the scientific theme lines with insights
  • Comprehensive and practical experience in investment execution

林思博
Sibo Lin

MBA from Tsinghua University, B.S in Biology from Peking University
Investment Director
  • MBA from Tsinghua University, B.S in Biology from Peking University
  • Years of experience in the field of life science industry and markets investment
  • Comprehensive understanding and judgment of the life science industry
  • Rich sources in industrial connection and primary market network

沈凯月
Kaiyue Shen

Juris Master from Peking University, B.A and LL.B from China Foreign Affairs University
Legal Director
  • Juris Master from Peking University, B.A and LL.B from China Foreign Affairs University
  • Years of work experience in the prestigious law firm
  • Extensive experience in the field of private equity fund establishment and operation

李天奇,Ph.D.
Tianqi Li,Ph.D.

Ph.D. and B.S. in Biology from Tsinghua University
Associate
  • Ph.D. and B.S. in Biology from Tsinghua University
  • Solid academic background and research experience
  • Deep research capability in life science